Capricor Therapeutics (NASDAQ: CAPR) stock has soared more than 35% since the FDA extended its review of the company's Duchenne muscular dystrophy therapy, deramiocel, by three months.

‍

The new decision date is Nov. 22, giving regulators additional time to review new 24-month clinical data and analyses submitted by Capricor. Normally, an FDA delay isn't something investors celebrate, but this one is different.

‍

Capricor entered the summer facing serious questions about whether deramiocel could win approval at all. In July, an FDA advisory committee voted 9-3 against whether the available evidence demonstrated the therapy's effectiveness for treating cardiomyopathy in patients with Duchenne muscular dystrophy. FDA staff had also raised concerns about aspects of the company's clinical analysis. That made the upcoming FDA decision a major risk for Capricor.

‍

But instead of simply waiting for that decision, the company submitted additional data and asked the FDA to consider a narrower indication focused on preserving upper-limb function.

‍

The FDA agreed to review it.

‍

Why the extension matters

‍

Deramiocel is an experimental cell therapy designed to treat Duchenne muscular dystrophy, a rare genetic disease that causes progressive muscle deterioration and primarily affects boys. Roughly 15,000 people in the U.S. have the disease.

‍

Capricor's new submission includes 24-month open-label extension data from its Phase 3 HOPE-3 trial, along with additional analyses.

‍

To be sure, HOPE-3 met its primary endpoint for upper-limb function, demonstrating a statistically significant slowing of disease progression as measured by PUL 2.0. That's essentially a test of how well Duchenne patients can continue using their shoulders, arms and hands as the disease progresses.

‍

That matters because losing upper-limb function can have an enormous effect on independence. Simple activities such as eating, using a phone or operating a wheelchair become increasingly difficult as Duchenne progresses.

‍

Capricor is now effectively asking the FDA to judge deramiocel on its ability to preserve that function rather than focusing primarily on its effects on the heart.

‍

The agency classified the new submission as a major amendment, triggering the three-month extension. Capricor says the FDA cited the significant unmet medical need in Duchenne when accepting the amendment for review.

‍

Why the stock soared

‍

The 35% move doesn't mean investors suddenly believe approval is guaranteed.

‍

Far from it.

‍

The FDA has already rejected deramiocel once. The advisory committee's 9-3 vote last month wasn't encouraging, either. Regulators have also questioned parts of Capricor's analysis.

‍

But the extension gives the company something it badly needed: another path toward approval.

‍

Instead of an immediate decision based largely on evidence that had already drawn substantial regulatory criticism, the FDA will now evaluate additional long-term data and a more narrowly defined indication.

‍

That explains why the market treated the delay as good news.

‍

The risk hasn't disappeared

‍

Capricor remains a highly speculative biotech stock.

‍

The FDA isn't required to follow the advisory committee's recommendation, but a 9-3 vote against the efficacy evidence can't simply be ignored. Regulators will now have to decide whether the additional data are strong enough to address those concerns and whether the evidence supporting upper-limb function warrants approval.

‍

If the answer is yes, deramiocel could become an important treatment option for a devastating disease with limited therapeutic choices.

‍

If the answer is no, Capricor could face another major regulatory setback.

‍

For now, however, the FDA's willingness to review the additional data means deramiocel is still very much alive. And for investors who feared the regulatory door was about to close, that was enough to send Capricor shares sharply higher.

‍